Full-Time

Lead Clinical Study Manager

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$116k - $182.3k/yr

+ Short-term and/or long-term incentives + 401(k) company match

Massachusetts, USA

Remote

Requires approximately 5–20% travel, including overnight and international travel.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Risk Management

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A BS/BA is required, preferably in a health-related, life science, or technology-related field, or an equivalent combination of education, training, and experience.
  • At least 6 years of experience in the pharmaceutical industry and/or a clinical research organization, including at least 4 years of clinical study management or oversight.
  • Experience with either early-phase clinical studies or Phase 2 and 3 studies, and with global or international studies or programs.
  • Knowledge of global regulatory and compliance requirements for clinical research, including United States Code of Federal Regulations, European Union Clinical Trial Directive, and International Council for Harmonisation Good Clinical Practice requirements.
  • Awareness of local country requirements for clinical research.
  • Demonstrated excellence in project and program management and matrix leadership.
  • Strong communication, teamwork, organizational, interpersonal, and problem-solving skills.
  • Fluent business English, both oral and written.
  • Ability to travel approximately 5–20%, including overnight and international travel.
Responsibilities
  • Lead study operational strategy and planning and oversee execution of clinical studies for assigned clinical programs in support of the Clinical Development Plan.
  • Oversee study execution in compliance with quality standards, including International Council for Harmonisation Good Clinical Practice, local regulations, and Takeda standard operating procedures, while maintaining schedule and budget.
  • Oversee strategic partners, contract research organizations, and third-party vendors to meet Takeda obligations and business objectives.
  • Provide subject matter expertise and operational input into protocol synopses, final protocols, and other study-related documents.
  • Assess operational feasibility, including patient and site burden, validate budgets, participate in country and site feasibility and selection, and align study execution plans with program strategy.
  • Ensure new team members and vendors are appropriately onboarded.
  • Lead development of the operational strategy during early engagement with strategic partners and contract research organizations, including accurate assumptions and robust risk-management plans.
  • Provide oversight, support, and guidance to strategic partners and contract research organizations so study issues are addressed and resolved rapidly.
  • Plan and manage study budgets and oversee external study-execution spend in collaboration with clinical operations program leaders, global program management, and Finance.
  • Communicate study status, costs, and issues to clinical operations program leaders and serve as an escalation point for third-party vendors.
  • Oversee strategic partner, contract research organization, and vendor selection, budget and contract negotiation, and performance supervision; escalate issues to governance committees when warranted.
  • Review and approve key monitoring documents and plans and periodically review monitoring outputs, decisions, and actions.
  • Review and endorse relevant study plans.
  • Manage and attend study team meetings when necessary and regularly review meeting agendas and minutes.
  • Review outcomes and actions related to protocol-deviation reviews to identify trends across sites and studies.
  • Document and monitor study-level issues, risks, and decisions and implement appropriate mitigation strategies.
  • Partner with data management to review and pressure-test database timelines and plans and link the filing, registration, and data-generation strategy to the database-lock and clinical study report tactical plan.
  • Ensure studies remain inspection-ready and support preparation for and attendance at regulatory inspections.
  • Represent the Lead Clinical Study Manager role in functional initiatives and working groups.
  • Support onboarding and mentor new or junior clinical study managers.
  • Assist the clinical operations program lead as required.
Desired Qualifications
  • Experience in more than one therapeutic area is advantageous.
  • A health-related, life science, or technology-related BS/BA field is preferred.
  • Advanced degrees such as a Master or Doctorate may supplement experience requirements.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval for MIMRYLO unlocks near-term U.S. oncology revenue.
  • Takeda expects ORZEYFUL U.S. launch by November 2026, pending DEA scheduling.
  • Q1 FY2026 new launches grew 22.6%, offsetting mature-brand declines and supporting guidance.

What critics are saying

  • May 18, 2026 AMITIZA verdict exposed Takeda to $2.6 billion treble-damage risk.
  • Takeda plans 4,500 FY2026 cuts, signaling launch execution pressure and organizational churn.
  • Patent erosion crushed VYVANSE sales 60.7% at constant currency in Q1 FY2026.

What makes Takeda unique

  • ORZEYFUL became the first orexin agonist approved for narcolepsy type 1 in 2026.
  • MIMRYLO offers first-in-class hepcidin mimetic therapy for polycythemia vera after FDA approval.
  • Takeda pairs global scale with Japanese discovery, including Shonan-led neurology innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Sep 9th, 2026
Trialbee unveils AI-powered patient screening chatbot at DPHARM 2026

Trialbee, a patient recruitment platform provider, will present at DPHARM 2026 in Boston on 15-16 September. The Swedish-American company will unveil AI-powered patient screening in its Honey Platform, enabling conversational AI chatbots to conduct initial candidate assessments whilst giving patients the option to speak with recruitment specialists. Trialbee will present jointly with pharmaceutical company Takeda on integrating their respective platforms to build research-ready patient communities that extend beyond single trials. The company will also participate in a panel discussing AI applications at clinical trial sites. The Honey Platform has added several AI features this year, including candidate summaries, duplicate detection, and recruitment data analysis. Trialbee supports over 6,000 research sites across 50 countries and reports a 91% repeat business rate with biopharmaceutical companies.

Associated Press
Sep 9th, 2026
Onco360 selected as specialty pharmacy partner for rare blood cancer drug MIMRYLO

Onco360, a US independent speciality pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO (rusfertide). The treatment is indicated for erythrocytosis in adults with polycythemia vera. MIMRYLO is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. This inhibition reduces iron availability for red blood cell production, resulting in lower hematocrit levels. The drug's approval was based on the phase 3 VERIFY study, a global, randomised, open-label clinical trial. The primary endpoint measured the proportion of patients achieving response during weeks 20-32, defined as the absence of phlebotomy eligibility. The most common adverse reactions were injection site reactions at 56% and anaemia at 16%.

Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.